New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.
What happened
FDA inspected New Life Pharma's drug manufacturing facility in Northvale, NJ, from February 3 to February 13, 2026. FDA found that the firm made unapproved semaglutide and tirzepatide sterile multi-dose vials, misstated its registration, failed to list drugs, and lacked basic sterility controls such as media fills, airflow studies, cleaning validation, and environmental monitoring. FDA also said investigators were denied access to two areas labeled "Area Not In Use," and the firm's March 6, 2026 response was inadequate.
What FDA found
The firm sold semaglutide and tirzepatide sterile multi-dose vials as new drugs without FDA-approved applications.
Section 505(a), 21 U.S.C. 355(a)The firm did not properly register or list its drugs with FDA and registered as an OTC monograph contract manufacturer even though it made unapproved prescription drugs.
Section 502(o), 21 U.S.C. 352(o); section 510, 21 U.S.C. 360; 21 CFR 207.25(f), 207.41The firm did not validate or control sterile manufacturing, including no media fills, smoke studies, cleaning validation, routine environmental monitoring, or adequate ISO 5 critical-area support.
21 CFR 211.113(b)The quality unit failed to ensure CGMP compliance, including missing production procedures, component testing, sterility and pyrogen testing, cleaning and maintenance procedures, and stability-supported expiration dates.
21 CFR 211.22; 211.100(a); 211.84(d)(1) and (2); 211.167(a); 211.67(b); 211.137(a)The firm refused FDA investigators access to two manufacturing areas labeled "Area Not In Use."
Section 501(j), 21 U.S.C. 351(j); section 704(a), 21 U.S.C. 374(a)
What FDA wants
FDA asks the firm to respond in writing within 15 working days with corrective actions and prevention plans, or with reasons and a schedule if more time is needed. FDA also asks New Life Pharma to confirm that it will not manufacture drugs in the future.
Who should pay attention
- med spas and cosmetic surgery practices that bought these vials
- clinics and pharmacies sourcing compounded or unapproved GLP-1 drugs
- sterile drug manufacturers and contractors with FDA registration and listing duties
This is a summary. Read the original letter on fda.gov.